Ingersoll Rand (IR) Q2 2026 Earnings Call Transcript

Ingersoll Rand reported Q2 revenue of $2,048.8M (+9% Y/Y) and adjusted EPS of $0.86 (+7% Y/Y), but adjusted EBITDA margin fell 160 bps to 25.4% on China inflation and higher corporate costs. Management raised full-year 2026 revenue guidance to +4.5% to +6.5% (200 bps higher at the midpoint) and guided adjusted EPS to $3.45–$3.57, expecting results to finish toward the high end, with margin normalization in 2H. Liquidity was $3.8B (incl. $1.2B cash) and net debt leverage stayed at 1.7x after a Moody’s one-notch upgrade to Baa1; the quarter also saw $110M deployed to acquisitions and a free-cash-flow increase of 28% to $268.9M.

Analysis

IR looks better than a simple earnings beat because the mix is quietly improving: more recurring aftermarket, better P&ST content, and a long-cycle book that is likely pushing revenue into 2027 rather than disappearing. That is the kind of setup that can support multiple expansion if the next two quarters confirm that orders are not just timing noise. Second-order, the winners are IR itself and adjacent bolt-on targets in filtration, vacuum, and fluid handling; the losers are more project-heavy industrial peers with thinner service revenue and weaker pricing discipline in China.

The risk is that the company raised revenue but not EBITDA, which tells you operating leverage is being absorbed by inflation, commercial spend, and overhead rather than dropping straight to the bottom line. In the next 1-3 months, the stock will trade on whether July order strength persists into August/September and whether Q3 shows sequential margin recovery; over 6-18 months, the thesis depends on China normalizing and P&ST holding a mid-30s margin trajectory. If ITS margins fail to inflect or China pricing stays weak, the premium case collapses quickly.

Consensus is probably over-focusing on the China price issue and underweighting the backlog build plus balance-sheet flexibility. The contrarian view is that this is not yet a clean secular compounder; a lot of the upside is still conditional on execution, and the current move can be overdone if investors confuse order timing with a new demand regime. The important tell is not management commentary, but whether pricing and mix drive actual margin expansion in the next quarter.

Key Decisions for Investors

• Buy IR on post-earnings weakness for a 1-3 month trade; thesis is 8-12% upside if July order strength translates into Q3 revisions and sequential margin recovery.
• Pair long IR / short XLI for the next 3-6 months to isolate company-specific backlog, aftermarket, and P&ST quality versus broad industrial beta; cut the pair if IR fails to outperform after the next print.
• Overweight IR versus more project-exposed industrial peers such as GGG and DOV over the next quarter; IR has better recurring revenue and better visibility into FY27 backlog conversion.
• Set a hard alert on Q3 margin progression: if ITS EBITDA margin does not improve sequentially from Q2, trim the position because the market will stop paying for the revenue beat without operating leverage.
• If buying options, prefer 6-12 month call spreads on IR only after a pullback of roughly 5% or more; avoid chasing upside after a gap-up because the catalyst is confirmation, not a single data point.